Abstract 4429: Comparison of afatinib and erlotinib as radiosensitizing agents in bladder cancer cells

Abstract Erlotinib is a first-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor and have well-established efficacy in non-small cell lung cancer patients with activating EGFR mutations. Afatinib, on the other hand, is a second-generation EGFR tyrosine kinase inhibitor with...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 73; no. 8_Supplement; p. 4429
Main Authors Tsai, Yu-Chieh, Tuan, Tsung-Fan, Ho, Pei-Yin, Liu, Wei-Lin, Chang, Liang-Yu, Pu, Yeong-Shiau, Cheng, Ann-Lii, Chen, Jason Chia-Hsien
Format Journal Article
LanguageEnglish
Published 15.04.2013
Online AccessGet full text

Cover

Be the first to leave a comment!
You must be logged in first